Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$135,000.00

Identification of Novel Inhibitors of the Acquired EGFR C797S Mutation in Non-Small Cell Lung Cancer

EF 2015-16

Résumé
Lung cancer, and in particular the most common subtype non-small cell lung cancer (NSCLC), representing 80% of all lung tumors, is the leading cause of cancer-related mortality worldwide. Proteins are the basic building blocks of a cell, which carry out diverse and crucial functions. Abnormally functioning proteins can lead to disease such as various types of cancers. Here, we propose to study abnormal proteins on the surface of human cells (also called receptors), which are associated with non-small cell lung cancer (NSCLC) using a new technology developed by our research laboratory in hopes of getting a better understanding of this widespread and deadly form of cancer. We foresee that the outcome of our proposed study will benefit cancer research in two ways. Firstly, it will increase our understanding of important molecular events of NSCLC. Secondly, we will be able to identify potential targets that can be used as therapeutic targets. This research will help other researchers in the field develop better, more specific treatments for lung cancer that are hard to treat, especially when patients have run out of therapeutic options.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
338933
Name
Saraon Punit
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Identification of Novel Inhibitors of the Acquired EGFR C797S Mutation in Non-Small Cell Lung Cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cell Signalling; Epidermal Growth Factor Receptor (Egfr); High-Throughput Screening; Mammalian Membrane Two-Hybrid (Mamth) Assay; Non-Small Cell Lung Cancer; Protein-Protein Interactions; Therapeutic Target
Abstract
Lung cancer, and in particular the most common subtype non-small cell lung cancer (NSCLC), representing 80% of all lung tumors, is the leading cause of cancer-related mortality worldwide. Proteins are the basic building blocks of a cell, which carry out diverse and crucial functions. Abnormally functioning proteins can lead to disease such as various types of cancers. Here, we propose to study abnormal proteins on the surface of human cells (also called receptors), which are associated with non-small cell lung cancer (NSCLC) using a new technology developed by our research laboratory in hopes of getting a better understanding of this widespread and deadly form of cancer. We foresee that the outcome of our proposed study will benefit cancer research in two ways. Firstly, it will increase our understanding of important molecular events of NSCLC. Secondly, we will be able to identify potential targets that can be used as therapeutic targets. This research will help other researchers in the field develop better, more specific treatments for lung cancer that are hard to treat, especially when patients have run out of therapeutic options.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Saraon, Punit
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~